2020 (v1)
Publication
No description
Uploaded on: April 14, 2023
-
-
2021 (v1)Publication
Background: Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women with highly active disease who plan a pregnancy or have an unplanned pregnancy, after...
Uploaded on: October 11, 2023 -
2021 (v1)Publication
BACKGROUND: Data regarding the predictive value of optical coherence tomography (OCT)-derived measures are lacking, especially in progressive multiple sclerosis (PMS). Accordingly, we aimed at investigating whether a single OCT assessment can predict a disability risk in both relapsing-remitting MS (RRMS) and PMS. METHODS: One hundred one...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2020 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2021 (v1)Publication
During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients experienced a delay in treatment based on MS...
Uploaded on: March 27, 2023